Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Anna Skipetrova"'
Autor:
Ngoc Huu Tran, Danaya Chansinghakul, Chia Yin Chong, Chian Yong Low, Lynette P. Shek, Chan Quang Luong, Carina Frago, T. Anh Wartel, Sunny Sun, Anna Skipetrova, Alain Bouckenooghe
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 15, Iss 10, Pp 2315-2327 (2019)
Dengue is prevalent in the Asia-Pacific region. Participants of two immunogenicity and safety phase II studies conducted in Singapore and Vietnam (NCT0088089 and NCT00875524, respectively) were followed for up to four years after third vaccine dose o
Externí odkaz:
https://doaj.org/article/a0e26386e5e24f5cb85306817c238951
Autor:
Judith Kirstein, William Douglas, Manoj Thakur, Mark Boaz, Thomas Papa, Anna Skipetrova, Eric Plennevaux
Publikováno v:
BMC Infectious Diseases, Vol 18, Iss 1, Pp 1-11 (2018)
Abstract Background The live attenuated tetravalent dengue vaccine (CYD-TDV) is licensed using a 0-, 6- and 12-month schedule in dengue-endemic areas. An effective shorter schedule may provide more rapid, optimal protection of targeted populations du
Externí odkaz:
https://doaj.org/article/5bf4c4833544458d96b6422ee2339d2c
Autor:
Bruno Guy, Fernando Noriega, R. Leon Ochiai, Maïna L’azou, Valentine Delore, Anna Skipetrova, François Verdier, Laurent Coudeville, Stephen Savarino, Nicholas Jackson
Publikováno v:
Expert Review of Vaccines, Vol 16, Iss 7, Pp 671-684 (2017)
Introduction: Dengue is an important and still growing public health problem associated with substantial morbidity, as well as significant social and economic impact. The present review describes the main features and development of the first dengue
Externí odkaz:
https://doaj.org/article/1ec8f753909b486bb2894b85ecb0c2bb
Autor:
Sophia Gailhardou, Anna Skipetrova, Gustavo H Dayan, John Jezorwski, Melanie Saville, Diane Van der Vliet, T Anh Wartel
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 10, Iss 7, p e0004821 (2016)
A recombinant live attenuated tetravalent dengue vaccine (CYD-TDV) has been shown to be efficacious in preventing virologically-confirmed dengue disease, severe dengue disease and dengue hospitalization in children aged 2-16 years in Asia and Latin A
Externí odkaz:
https://doaj.org/article/4a9955c0bd7e4bf0bcf5d650f0e1b0a3
Publikováno v:
Vaccine. 36:3345-3350
Background The live, attenuated, tetravalent dengue vaccine (CYD-TDV) is licensed in several endemic countries and contraindicated during pregnancy. Inadvertent vaccination during pregnancy may occur during clinical trials that include women of child
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2dade5d51604175aa90b425afb20b622
https://doi.org/10.1016/j.vaccine.2018.04.050
https://doi.org/10.1016/j.vaccine.2018.04.050
Autor:
Valentine Delore, Laurent Coudeville, Maïna L’Azou, Stephen Savarino, R. Leon Ochiai, Bruno Guy, Nicholas Jackson, Anna Skipetrova, François Verdier, Fernando Noriega
Publikováno v:
Expert Review of Vaccines. 16:671-684
Dengue is an important and still growing public health problem associated with substantial morbidity, as well as significant social and economic impact. The present review describes the main features and development of the first dengue vaccine (CYD-T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebf82e394af871278681f989eab87f0d
https://doi.org/10.1080/14760584.2017.1335201
https://doi.org/10.1080/14760584.2017.1335201
Autor:
Mark Boaz, Eric Plennevaux, Thomas Papa, Anna Skipetrova, Manoj Thakur, William Douglas, Judith Kirstein
Publikováno v:
BMC Infectious Diseases, Vol 18, Iss 1, Pp 1-11 (2018)
Background The live attenuated tetravalent dengue vaccine (CYD-TDV) is licensed using a 0-, 6- and 12-month schedule in dengue-endemic areas. An effective shorter schedule may provide more rapid, optimal protection of targeted populations during vacc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4aea26cdf818e2aadd8ab1e32bdc6166
https://pubmed.ncbi.nlm.nih.gov/30241510
https://pubmed.ncbi.nlm.nih.gov/30241510
Autor:
Diane van der Vliet, Sophia Gailhardou, Melanie Saville, T. Anh Wartel, Anna Skipetrova, John Jezorwski, Gustavo H. Dayan
Publikováno v:
PLoS Neglected Tropical Diseases
PLoS Neglected Tropical Diseases, Vol 10, Iss 7, p e0004821 (2016)
PLoS Neglected Tropical Diseases, Vol 10, Iss 7, p e0004821 (2016)
A recombinant live attenuated tetravalent dengue vaccine (CYD-TDV) has been shown to be efficacious in preventing virologically-confirmed dengue disease, severe dengue disease and dengue hospitalization in children aged 2–16 years in Asia and Latin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4f28c78589d86a5219e426d65328b20
https://pubmed.ncbi.nlm.nih.gov/27414655
https://pubmed.ncbi.nlm.nih.gov/27414655